Gene Signal SAS   Report issue

For profit Phase 3
Founded: Lausanne Switzerland (2000)

Organization Overview

First Clinical Trial
2017
NCT02947867
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now